Case details

Merger control

Case reference

CCENT/2010/35 - Fujirebio / Innogenetics

Acquiring

Fujirebio Inc.

Description

a subsidiary of the company Miraca Holdings Inc. (Miraca Group, quoted on the Tokyo Stock Exchange), which produces and markets in-vitro diagnostic (IVD) tests, and IVD reagents and test systems. Fujirebio has no affiliate, associate or subsidiary companies or other assets in Portugal: its sales are carried out via its subsidiary Fujirebio Diagnostics AB.

Acquired

Innogenetics NV

Description

a multinational company that develops and markets a wide range of IVD products in the fields of infectious diseases, genetic tests, transplants and neuro-degenerative diseases, with a special focus on molecular diagnostic systems and multi-parametric tests. Innogenetics has no affiliate, associate or subsidiary companies in Portugal: it markets its products through an independent distributor.

Sector

Extractive and manufacturing Industries

Activity (NACE)

C2120 - Manufacture of pharmaceutical preparations

Applicable legislation

Art. 9(1)(a) (Law 18)

Notification thresholds

Market share

Type of merger

Conglomerate

Cooperation with sector regulators

Status

Closed

Type of Investigation

Phase 1

AdC’s decision

Case description

Notified on 29 July 2010, this merger operation consists of the acquisition, by the undertaking Fujirebio Inc. ("Fujirebio") of exclusive control of the company Innogenetics NV ("Innogenetics"), by means of the acquisition of its share capital.

Timeline

2010-09-02

Competition Authority Council adopts a decision of non-opposition to merger operation 35/2010 - Fujirebio / Innogenetics.

2010-08-06

Publication of the announcement - The undertaking Fujirebio Inc. ("Fujirebio") notifies acquisition of exclusive control of the company Innogenetics NV ("Innogenetics"), by means of the acquisition of its share capital.

Top links

Case details